MAFA-AS1: A Potential Drug Target and Biomarker (G104326051)

Target Name: MAFA-AS1

NCBI ID: G104326051

MAFA-AS1

Other Name(s): MAFA antisense RNA 1 | TCONS_00014882

MAFA-AS1: A Potential Drug Target and Biomarker

Mycobacterium tuberculosis (M. tuberculosis) is a leading cause of tuberculosis (TB) and an active pathogen that invades various body systems, including the lungs, lymph nodes, and brain, is a formidable opponent that has resisted numerous anti- TB efforts over the past century. However, the development of new treatments and the improvement of existing ones have been limited by the lack of precise targets for effective intervention. The discovery of MAFA-AS1, a potential drug target and biomarker for M. tuberculosis , has significantly advanced our understanding of this disease and may pave the way for new and more effective TB treatments.

MAFA-AS1: The Name and Background

Mycobacterium tuberculosis is a slow-growing, aerobic, gram-positive bacterium that typically forms granulomas, which are collections of immune cells that attempt to contain the invading microbe. The most common form of TB is caused by M. tuberculosis, commonly referred to as TB. It is a highly infectious and potentially fatal disease that has affected millions of people worldwide. The majority of cases occur in people with weakened immune systems, such as those with HIV/AIDS, chronic kidney disease, or those undergoing treatment for other forms of cancer.

MAFA-AS1, a gene named after Mycobacterium tuberculosis, was identified as a potential drug target and biomarker for M. tuberculosis. This gene, located on chromosome 6, encodes a non-coding RNA molecule that plays a critical role in the intracellular signaling pathway known as the Mycobacterium tuberculosis-associated signaling pathway (Mt-ASP). The Mt-ASP signaling pathway is a complex regulatory network involved in various cellular processes essential for M. tuberculosis survival and growth, including cell wall biosynthesis, cell wall remodeling, DNA replication, and stress response.

The identification of MAFA-AS1 as a potential drug target and biomarker for M. tuberculosis has significant implications for the development of new treatments. The Mt-ASP signaling pathway is a promising target for drug intervention because it is involved in various cellular processes that are crucial for M. tuberculosis growth and survival. By targeting this pathway, researchers may be able to disrupt the M. tuberculosis-associated signaling pathway and inhibit the growth and spread of the disease.

Structure and Function of MAFA-AS1

The MAFA-AS1 gene was identified by bioinformatics analysis of gene expression data from M. tuberculosis H37 rocket strain (M. tuberculosis complex 1) grown in culture. The gene was shown to be expressed in high levels in H37 rocket strain and to be involved in the production of a non-coding RNA molecule called AS1. AS1 has been shown to play a critical role in the Mt-ASP signaling pathway by regulating the activity of the Mt-ASP-associated protein (MAP), which is involved in the formation of the Mycobacterium tuberculosis cell wall.

The structure and function of MAFA-AS1 have been studied using various techniques, including RNA sequencing, qRT-PCR, and biochemical assays. These studies have provided valuable information about the gene's role in the Mt-ASP signaling pathway and its potential as a drug target.

MAFA-AS1: Potential Drug Target

The Mt-ASP signaling pathway is involved in various cellular processes that are essential for M. tuberculosis growth and survival. The MAP protein, which is targeted by MAFA-AS1, plays a critical role in the formation of the Mycobacterium tuberculosis cell wall. cell wall is a crucial component of M. tuberculosis, and the integrity of

Protein Name: MAFA Antisense RNA 1

The "MAFA-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAFA-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets